linjc16/ctgov huggingface dataset:
Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in postoperative supraventricular tachyarrhythmias.

Official Title
-----------------
Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan

Conditions
-----------------
Postoperative Supraventricular Tachyarrythmia

Intervention / Treatment
-----------------
* Drug: ONO-1101


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20 years or older Postoperative supraventricular tachyarrhythmias Within 7 days postoperatively Other inclusion criteria as specified in the protocol Exclusion Criteria: Acute myocardial infarction (within 1 month after onset) Severe heart failure [New York Heart Association (NYHA) functional class III or higher] Atrioventricular block (grade II or higher), or sick sinus syndrome Other exclusion criteria as specified in the protocol

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 84 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ONO-1101|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients who met the heart rate reduction criteria (20% reduction from the baseline heart rate and a heart rate of <100 beats/min) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart rate, blood pressure, rate-pressure-product and ECG |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ONO-1101, Landiolol Hydrochloride, Postoperative, supraventricular tachyarrhythmia
Indirect Ultrasonographic Findings for Parametrial Involvement in Deep Endometriosis

Study Overview
=================
Brief Summary
-----------------
This study evaluated the use of ultrasonographic findings as a first-line imaging tool to raise indirect suspicion of parametrial involvement in women suspected of having severe endometriosis (DE).

Detailed Description
-----------------
Ultrasonographic findings will be conventionally divided in: concomitant DE nodules indirect DE signs

Official Title
-----------------
Indirect Ultrasonographic Findings Predicting Parametrial Involvement in Severe Deep Endometriosis

Conditions
-----------------
Endometriosis, Deep Endometriosis

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with suspected deep endometriosis undergoing surgical approach Exclusion Criteria: patients with a previous surgical diagnosis of endometriosis pazients with radiological evidence of parametrial endometriosis patients who could not undergo transvaginal and/or transabdominal ultrasound for any technical reason

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women with surgical diagnosis of parametrial endometriosis<br>This cohort will include patients with surgical diagnosis of parametrial endometriosis | Diagnostic Test: Ultrasound<br>* Preoperative transvaginal/transabdominal ultrasonography done according to IDEA criteria.<br>|
| Women without surgical diagnosis of parametrial endometriosis<br>This cohort will include patients without surgical diagnosis of parametrial endometriosis | Diagnostic Test: Ultrasound<br>* Preoperative transvaginal/transabdominal ultrasonography done according to IDEA criteria.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with a surgical diagnosis of parametrial endometriosis |  | At surgery | 
| Number of significant ultrasonographic concomitant DE nodules predicting surgical involvement |  | 1 week before surgical approach | 
| Number of significant ultrasonographic indirect DE signs predicting surgical involvement |  | 1 week before surgical approach | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parametrial endometriosis, Deep endometriosis, Transvaginal Ultrasound
Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate how we can detect Alzheimer's disease early by using an online memory test and a simple blood test. These new methods for early diagnosis could allow people to begin treatment sooner, with the potential to improve the lives of millions of people.

Official Title
-----------------
Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease

Conditions
-----------------
Alzheimer Disease

Intervention / Treatment
-----------------
* Other: Cognitive Assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Subjects must meet the following criteria for entry into the study: Male or female > 65 years of age at the time of consent; Understand and voluntarily sign an informed consent form; Inclusion criteria is assessed at both e-consent (assessed by participant's self-reporting of age and understanding) and in-person consent at TRI (assessed by clinical research coordinators in TRI). Exclusion Criteria Subjects who meet any of the following criteria will not be eligible for entry into the study: Subjects who are unable to hear and see well enough to complete the assessments; Prior diagnosis of dementia or Alzheimer's disease documented in their medical record and/or as diagnosed by a physician; Exclusion criteria is assessed by by participant's self-reporting of understanding and not having a prior diagnosis of dementia at the time of e-consentand visit 1 at TRI. ).

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| General study participants (patients)<br> | Other: Cognitive Assessment<br>* Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.<br>* Other names: MoCA;|
| Healthcare Practitioners<br> | |
| Pre-Program Chart Audits (100 patients what will be chart audited)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantify the proportion of individuals at least 65 years old with cognitive impairment |  | Less than 6 months |
Validation of Apnea LinkTM for Sleep Apnea Syndrome Screening in a Bariatric Population

Study Overview
=================
Brief Summary
-----------------
Sleep apnea syndrome (OSA) frequently occurs in obese population undergoing bariatric surgery. There is a need for alternative screening tools for sleep apnea detection in the pre-operative period. The investigators would like to compare ApneaLink and complete polysomnography in this population.

Detailed Description
-----------------
OSA can occur in up to 78% of patients undergoing bariatric surgery(1). Moderate to severe case will benefit from CPAP therapy, that can help avoiding post-operative complications(2). In this population, the investigators propose complete attended in-hospital polysomnography (PSG)in patients with a clinical high probability of OSA. According to obesity epidemics (3), waiting list for PSG in sleep labs is every day longer. The investigators want to assess sensitivity and specificity of a new portable screening tool, ApneaLink, to detect OSA in a bariatric population. Design: monocentric and prospective study Methods: Patients: - OSA suspicion based on : symptoms and signs (snoring, apneas , neck circumference >38 (women) or 43cm (men)) BMI > 50 BMI > 40, > 40 y BMI > 35, men, hypertension increased serum Bicarbonate Polyglobulia Measurements Polysomnography in sleep lab with concommitant recording performed with Apnea LinkTM (nasal flow and oxymétry recording). between 2 weeks : recording performed with Apnea LinkTM (nasal flow and oxymétry recording)at home.

Official Title
-----------------
Validation of Apnea LinkTM (ResMed Corporation, Poway, California) for Sleep Apnea Syndrome Screening in a Bariatric Population

Conditions
-----------------
Sleep Apnea Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: obese patients > 18 years old in whom a bariatric surgery is planified and who have to undergo a polysomnography for OSA screening Exclusion Criteria: pulmonary, neurologic, neuromuscular disease < 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| bariatric population<br>obese patients in whom a bariatric surgery is planified | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with correct diagnosis of OSA with ApneaLink. Therefore, we will compare apnea-hypopnea index measured with ApneaLink with apnea-hypopnea index measured during polysomnography. |  | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sleep apnea, polysomnography, obesity, bariatric surgery
Blood Cell RNA-Based Cancer Detection

Study Overview
=================
Brief Summary
-----------------
Early diagnosis of cancer may provide patients with more treatment options and hopefully prolong survival. The purpose of this multi-center study is to collect peripheral blood from newly diagnosed cancer patients and healthy donors to establish a blood cell RNA-based model for the differentiation of cancer patients and healthy donors. The area under the receiver operating characteristic (AUROC), sensitivity and specificity of the test in the early detection of multiple cancers will be measured.

Official Title
-----------------
A Blinded Prospective Study on Development and Validation of the Blood Cell RNA-Based Cancer Detection

Conditions
-----------------
Neoplasms, Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Blood test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for All the Participants Age 18 years or older Provide informed consent Exclusion Criteria for All the Participants: Pregnancy or lactating women Received a blood transfusion within 1 month Received anti-cancer treatment within 3 years Known prior diagnosis of cancer Poor health status or unfit to tolerate blood draw

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cancer<br>Patients with new diagnosis of cancers | Diagnostic Test: Blood test<br>* RNA sequencing of peripheral blood cells<br>|
| Non-cancer<br>Healthy participants | Diagnostic Test: Blood test<br>* RNA sequencing of peripheral blood cells<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and specificity of cancer detection | Sensitivity and specificity of the early detection of 30 types of cancers of a blood cell RNA-based cancer detection test | 1 year | 
| Accuracy of TOO prediction | Accuracy of the tissue of origin (TOO) prediction of a blood cell RNA-based cancer detection test | 1 year |
Genetic Analysis of Familial Brain Aneurysms

Study Overview
=================
Brief Summary
-----------------
This study will investigate cerebral (brain) aneurysms and their possible inheritance patterns in families. It will try to determine how often brain aneurysms occur in families in which more than one member has had an aneurysm and to find the gene or genes that contribute to their development. People in families in which more than one family member had a cerebral aneurysm are eligible for this 1-day study. They will undergo the following procedures: Blood will be drawn (no more than 3 to 4 tablespoons) for research to identify genes that contribute to the development of brain aneurysms. A magnetic resonance angiograph (MRA) scan will be done to examine a specific brain area where aneurysms typically occur. Magnetic resonance imaging uses a strong magnetic field and radio waves to produce images of the brain and detect abnormalities. If a more detailed picture of the brain is needed than can be obtained with MRA, a more specific MRA scan will be done using a contrast dye to enhance the images. Patients may be invited to participate in related NIH research studies.

Detailed Description
-----------------
This study is designed to explore the genetics of familial cerebral aneurysms. Families in which more than one person has had a known cerebral aneurysm will be studied. Family histories will be obtained and participants identified who are willing to come to the NIH Clinical Center for an MRAngiograph and venipuncture. DNA will be isolated and linkage studies undertaken to identify loci involved in the etiology of familial cerebral aneurysms, using standard linkage approaches.

Official Title
-----------------
Linkage Analysis of Familial Intracranial Aneurysms

Conditions
-----------------
Intracranial Aneurysm

Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA: Participants and their relatives that are affected or at a higher risk for cerebral aneurysms will be enrolled in this protocol. EXCLUSION CRITERIA: For the MR Angiograph portion of the study, any participant that is not able to sign the Clinical Center consent form due to metal implants, pregnancy, claustrophobia, or an allergy to gadolinium as a contrast will be excluded from the imaging part of the study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intracranial Aneurysms, Cerebral, Loci, Susceptibility Genes, Cerebral Aneurysm, Familial Cerebral Aneurysm, Genetics
Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas

Study Overview
=================
Brief Summary
-----------------
The rationale for the proposed pilot study is to investigate the ability of PET-CT with F18-choline to detect and locate the parathyroid adenoma in patients with primary hyperparathyroidism and negative or non-contributory MIBI (Tc-99m sestamibi) and cervical ultrasound, in order to avoid unnecessary bilateral cervical exploration.

Official Title
-----------------
Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas

Conditions
-----------------
Hyperparathyroidism

Intervention / Treatment
-----------------
* Radiation: F18-choline PET examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient aged 18 years or more; Patient with a primary hyperparathyroidism and witj a negative or non-contriburatory MIBI parathyroid scintigraphy and neck ultrasonography, for which surgical resection is planned; Confirmation of the diagnosis of primary hyperparathyroidism on laboratory tests Affiliate to a social security system; Patient written informed consent. Exclusion Criteria: Patient deprived of liberty, under guardianship; Any medical or psychological condition witch could compromise the capacity of the patient to participate in the study; Pregnant or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: F18-choline PET<br>F18-choline PET examination will be performed before surgery | Radiation: F18-choline PET examination<br>* F18-choline PET examination will be performed before surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity (ability to identify and visualize the parathyroid adenoma) | Sensitivity of PET-CT with F18-choline (FCH) to identify and visualize the parathyroid adenoma in patients with primary hyperparathyroidism and negative or non-contributory parathyroid scintigraphy MIBI and cervical ultrasound | Up to 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
F18-choline
Lactoferrin Versus Iron Supplement in Irondeficiency Anemia and Weight Loss in Obese Children

Study Overview
=================
Brief Summary
-----------------
The effect of lactoferrin versus iron supplement in treating iron deficiency anemia and helping weight loss in obese school age children

Detailed Description
-----------------
Comparing iron versus lactoferrin as regard iron defiency anemia and weight loss in obese children

Official Title
-----------------
The Effect of Lactoferrin Versus Iron Supplement in Treating Iron Deficiency Anemia and Helping Weight Loss in Obese School Age Children

Conditions
-----------------
Obesity, Childhood

Intervention / Treatment
-----------------
* Drug: Iron Supplement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. children age will be between 6 -12 years old. 2. Presence of iron deficiency anemia, it will be diagnosed by CBC >> Hemoglobin level concentration below 11.5 g/dl. level of serum iron is below 30 µmol/l, level of ferritin is below 15 µg/dl Total iron binding capacity is more 480 µg/dlL. 3. children should be stable and free from chronic disease. 4. Body Mass index (BMI) should be ≥the 95th percentile for children and teens of the same age and sex. 5. there is not history of iron supplements in the 3 months before treatment. Exclusion Criteria: Father/mother refuses to participate in the study. Hospitalized patient. Non-anemic patient. Patients receiving iron supplements 3 months before enrollment. Patients with chronic diseases. personal or family history of allergy to cow's milk or infant formula, eczema, moderate-to-severe allergic rhinitis or asthma, or milk intolerance. severe anemia as Hemoglobin level concentration below 7 g/dl. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: obese children 1<br>iron supplementation | Drug: Iron Supplement<br>* in iron deficiency anemia<br>* Other names: lactoferrin;|
| Active Comparator: obese children 2<br>lactoferrin supplementation | Drug: Iron Supplement<br>* in iron deficiency anemia<br>* Other names: lactoferrin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| iron deficiency anemia | CBC and iron profile | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight | Weight and body copmositiin | 3 months |
Vitamin D Supplementation Can Improve Heart Function in Idiopathic Cardiomyopathy

Study Overview
=================
Brief Summary
-----------------
Vitamin D deficiency could be a high risk for cardiovascular diseases. It has been recently reported that vitamin D deficiency is another cause of heart failure and cardiomyopathies. It was found that vitamin D supplementation improved the heart function. The purpose of this study is to evaluate patients with idiopathic cardiomyopathies and determine whether vitamin D supplementation in cases where there is a deficiency, improves heart functioning.

Conditions
-----------------
Cardiomyopathy, Dilated

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamin D


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with idiopathic cardiomyopathy Exclusion Criteria: Post heart surgery Congenital heart disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients with cardiomyopathy<br>Patients with vitamin D deficiency and cardiomyopathy will receive supplementation with vitamin D 400 units per day for 6 months. | Dietary Supplement: Vitamin D<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with Improvement of heart function |  | 6 months |